Alpha 2.0
Login Register
» Authors » Dusan Kotasek

Dusan Kotasek

Explore the profile of Dusan Kotasek including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 30
Citations 560
Followers 0
Related Specialties
Oncology
General Medicine
General Surgery
Top 10 Co-Authors
Axel Le Cesne
Jean-Yves Blay
Paolo G Casali
Ian R Judson
Michael Hedenus
Antoine Italiano
Christos Karapetis
Ben Markman
Piotr Rutkowski
Jayesh Desai
Published In
J Clin Oncol
Invest New Drugs
Asia Pac J Clin Oncol
Cancer Chemother Pharmacol
JAMA Surg
Affiliations
Soon will be listed here.
Recent Articles
1.
Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study
Bishnoi S, Kotasek D, Aghmesheh M, Yau T, Cosman R, Prawira A, et al.
Cancer . 2024 Feb; 130(11):1991-2002. PMID: 38404184
Background: This study investigated the safety and efficacy of an anti-CTLA-4 monoclonal antibody (CS1002) as monotherapy and in combination with an anti-PD-1 monoclonal antibody (CS1003) in patients with advanced/metastatic solid...
2.
A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer
Day D, Park J, Coward J, Markman B, Lemech C, Kuo J, et al.
Br J Cancer . 2023 Sep; 129(10):1608-1618. PMID: 37731023
Background: We assessed nofazinlimab, an anti-PD-1 antibody, in solid tumors and combined with regorafenib in metastatic colorectal cancer (mCRC). Methods: This phase 1 study comprised nofazinlimab dose escalation (phase 1a)...
3.
Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer
Cho B, Yoh K, Perets R, Nagrial A, Spigel D, Gutierrez M, et al.
Lung Cancer . 2021 Aug; 159:162-170. PMID: 34371366
Objectives: This first-in-human phase I study (NCT03179436) investigated anti-cytotoxic T-lymphocyte-associated protein 4 monoclonal antibody quavonlimab and anti-programmed death 1 monoclonal antibody pembrolizumab in patients with advanced solid tumors. The study...
4.
Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study
Tie J, Wang Y, Cohen J, Li L, Hong W, Christie M, et al.
PLoS Med . 2021 May; 18(5):e1003620. PMID: 33939694
Background: In patients with resectable colorectal liver metastases (CRLM), the role of pre- and postoperative systemic therapy continues to be debated. Previous studies have shown that circulating tumor DNA (ctDNA)...
5.
Effects of a prescribed, supervised exercise programme on tumour disease progression in oncology patients undergoing anti-cancer therapy: a retrospective observational cohort study
Salamon G, Dougherty D, Whiting L, Crawford G, Stein B, Kotasek D
Intern Med J . 2020 Dec; 53(1):104-111. PMID: 33347696
Background: Exercise promotes numerous advantages in both health and disease, and is increasingly being acknowledged to improve overall survival in cancer patients. Preclinical studies indicate a direct effect on tumour...
6.
Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib
Gronchi A, Bonvalot S, Velasco A, Kotasek D, Rutkowski P, Hohenberger P, et al.
JAMA Surg . 2020 Apr; 155(6):e200397. PMID: 32236507
Importance: The association between quality of surgery and overall survival in patients affected by localized gastrointestinal stromal tumors (GIST) is not completely understood. Objective: To assess the risk of death...
7.
Primary pericardial mesothelioma presenting as multiple pericardial masses on CT
Raeside M, Gormly K, Neuhaus S, Kotasek D, James C
BJR Case Rep . 2018 Oct; 2(1):20150295. PMID: 30364446
We present the case of a 67-year-old male who was found to have multiple enhancing pericardial masses on CT imaging for investigation of weight loss and was subsequently diagnosed with...
8.
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors
Carducci M, Shaheen M, Markman B, Hurvitz S, Mahadevan D, Kotasek D, et al.
Invest New Drugs . 2018 Jul; 36(6):1060-1071. PMID: 29980894
Background Aurora kinase overexpression or amplifications are associated with high proliferation, poor prognosis, and therapeutic resistance in human tumors. AMG 900 is an investigational, oral, selective pan-Aurora kinase inhibitor. Methods...
9.
Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC
McKeage M, Kotasek D, Markman B, Hidalgo M, Millward M, Jameson M, et al.
Target Oncol . 2017 Dec; 13(1):89-98. PMID: 29188408
Background: Delta-like ligand 4-Notch (DLL4-Notch) signaling contributes to the maintenance of chemotherapy-resistant cancer stem cells and tumor vasculature. Objective: This phase IB trial of demcizumab, an IgG2 humanized monoclonal antibody...
10.
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian...
Casali P, Zalcberg J, Cesne A, Reichardt P, Blay J, Lindner L, et al.
J Clin Oncol . 2017 Apr; 35(15):1713-1720. PMID: 28362562
Purpose To report on the long-term results of a randomized trial comparing a standard dose (400 mg/d) versus a higher dose (800 mg/d) of imatinib in patients with metastatic or...